Study of CM310 for frequent COPD flare-ups
Part of Lungs & breathing clinical trials.
This study tests a new injectable medicine called CM310 for people with moderate to severe COPD who have chronic bronchitis and frequent flare-ups, despite using standard inhalers. It aims to see if CM310 can reduce flare-ups and improve breathing by targeting a specific type of inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 40 to 85 years old.
- You have had COPD for at least 1 year, and it is moderate to severe (based on breathing tests).
- You have a chronic cough with phlegm for at least 3 months in the last year.
- In the past year, you have had at least 2 moderate COPD flare-ups or 1 severe flare-up that required a hospital stay, despite using your regular inhalers.
- You have high levels of eosinophils (a type of white blood cell) in your blood (≥0.3 x 10^9/L).
- You are currently taking a combination of three inhalers (ICS + LABA + LAMA) or two inhalers if ICS is not suitable, for at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication called CM512 for people with moderate-to-severe COPD who still have flare-ups despite using their regular inhalers. It aims to see if adding this treatment can reduce flare-ups and improve quality of life.
This trial tests a new medicine called CM326 for people with moderate to severe COPD. It aims to see if the drug can reduce flare-ups and improve lung function.
This study tests whether a structured care program for COPD can lower how often your symptoms flare up. It may help by improving everyday management and preventing future worsening.
This study tests a new medicine called Lunsekimig for people with COPD that has frequent flare-ups and high eosinophil levels (a sign of inflammation). It aims to see if it can help control symptoms better than a placebo (a dummy treatment).
This study tests an oral tablet called RSS0343 for people with moderate to severe COPD. It aims to see if the tablet can improve lung function and reduce flare-ups when added to your current breathing treatments.
This study tests CM310 to see if it can improve asthma in people with moderate to severe asthma who are still having uncontrolled symptoms and severe flare-ups despite regular inhaler treatment. You may be eligible if your lung function and asthma control tests fit the study limits and you’ve had a recent severe exacerbation.
Hear when a new Chronic Obstructive Pulmonary Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.